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Endothelial dysfunction induced by oxidative stress and inﬂammation plays a critical role in the path-
ogenesis of cardiovascular diseases. The anesthetic sevoﬂurane confers cytoprotective effects through its
anti-inﬂammatory properties in various pathologies such as systemic inﬂammatory response syndrome
and ischemic-reperfusion injury but mechanism is unclear. We hypothesized that sevoﬂurane can pro-
tect against tumor necrosis factor (TNF)-a-induced endothelial dysfunction through promoting the
production of endothelium-dependent nitric oxide (NO). Primary cultured human umbilical vein
endothelial cells (HUVECs) were pretreated with different concentrations (0.5, 1.5 and 2.5 minimum
alveolar concentration, MAC) of sevoﬂurane for 30 min before TNF-a (10 ng/mL) stimulation for 4 h.
Sevoﬂurane pretreatment signiﬁcantly reduced TNF-a-induced VCAM-1, ICAM-1, IkBa, and NF-kB acti-
vation, and blocked leukocytes adhesion to HUVECs. Meanwhile, sevoﬂurane (1.5 and 2.5 MAC) signiﬁ-
cantly induced endothelial nitric oxide synthase (eNOS) phosphorylation and enhanced NO levels both
intracellularly and in the cell culture medium. All these cytoprotective effects of sevoﬂurane were
abrogated by NG-nitro-L-arginine methyl ester (L-NAME), a non-speciﬁc nitric oxide synthase inhibitor.
Collectively, these data indicate that sevoﬂurane protects against TNF-a -induced vascular endothelium
dysfunction through activation of eNOS/NO pathway and inhibition of NF-kB.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Endothelial cell activation and dysfunction play an important
role in various pathological inﬂammatory states such as systemic
inﬂammatory response syndrome (SIRS), ischemia-reperfusion
injury and rejection of graft tissue [1e3]. In these conditions, pro-
inﬂammatory cytokines (e.g. TNF-a) are released, and the nor-
mally “quiescent” endothelium becomes “activated”, leading to
expressions of multiple families of cell adhesion molecules (CAMs)
[4]. Excessive leukocytes accumulation can contribute to theiology, The Second Xiangya
Road No. 139, Changsha, Hu-
, ruanwei2001@hotmail.com
Inc. This is an open access article udevelopment of inﬂammatory injury. Many studies [5,6] aimed at
protection of endothelial cells against inﬂammatory injury have
shown a dramatic reduction in tissue injury and provided further
evidence of an important role of endothelial cells in determining
oxidative stress and attenuating infection.
Sevoﬂurane, one of the most commonly used volatile anes-
thetics, has been proven to be effective in combating oxidative
stress, inﬂammation, and protecting organs against stress-induced
injury in various conditions [7e9]. Sevoﬂurane preconditioning
signiﬁcantly attenuated TNF-a-induced permeability and activation
of p38 MAPK in rat pulmonary microvascular endothelial cells by
reducing ICAM-1 expression [10]. However, the underlying mech-
anism governing the cytoprotective effects of sevoﬂurane against
cytokine-induced toxicity in human endothelial cells has not been
fully deﬁned.
The endothelial isoform of nitric oxide synthase (eNOS) is a key
source of vascular nitric oxide (NO), a cell protectivemolecular withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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critical in the development and progression of tissue inﬂammatory
injury [12]. Volatile anesthetics have recently been shown to exert
protective effects on NO production [13e15]. Whether eNOS plays a
role in sevoﬂurane mediated anti-inﬂammation effects in endo-
thelial cells has not beenwell characterized. The present study thus
tested the hypotheses that anti-inﬂammatory effect of sevoﬂurane
is NO dependent in TNF-a-induced endothelial cells injury and
investigated the potential signaling cascades.
2. Material and methods
This investigation conformed to the principles outlined in the
Declaration of Helsinki for the use of human umbilical cord. The
informed consent was obtained from the donors, and the protocol
was approved by the Ethics Committee of Experimental Research,
Xiangya Medical College, Central South University.
2.1. Materials
Sources of materials were as follows: anti-VCAM-1, anti-ICAM-1
and anti-b-actin (Santa Cruz Biotechnology, CA); anti-IkBa, anti-NF-
kB, anti-iNOS, anti-nNOS, anti-p-eNOS, and anti-total eNOS (Cell
Signaling Technology, Boston, MA); sevoﬂurane (Maruishi Phar-
maceutical Co. Ltd., Osaka, Japan); tumor necrosis factor-a (TNF-a),Fig. 1. Sevoﬂurane inhibited TNF-a-induced expression of ICAM-1, VCAM-1 and leukocyte
ﬂurane for 30 min followed by TNF-a stimulus. Results of western blot (A) and real-time P
leukocytes were added to stimulated HUVECs, adherent cells were lysed and assayed by
with sevoﬂurane. The data were expressed as mean ± SD of the results from ﬁve separate exp
D indicates p < 0.01, DD indicates a p < 0.001 compared with TNF-a-treated cells.NOS inhibitor L-NAME and collagenase type II (Sigma Aldrich, St.
Louis, MO, U.S.).
2.2. Endothelial cell isolation and treatment
Primary cultures of HUVECs were performed as previously
described [16]. Brieﬂy, the cord was severed from the placenta soon
after birth, cannulated and perfused with 0.1% collagenase type II in
the umbilical vein. After incubation, the collagenase solution was
collected, sedimented, and resuspended, and the endothelial cells
were cultured in endothelial cell culture medium (ScienCell,
Carlsbad, CA, USA) in a humidiﬁed atmosphere containing 5% CO2
and 95% air at 37 C. Studies with HUVECs were conducted with
cells from passage two to ﬁve. The experimental protocol is illus-
trated in Figure S1, HUVECs were pretreated with or without L-
NAME 1 mM for 1 h before exposure to sevoﬂurane or air for
30 min, after which the cell growth medium was replaced with
phenol red-free and growth factor-free medium and then stimu-
lated with TNF-a for 4 h.
2.3. Exposure of cultured cells to sevoﬂurane
Anesthetic-enriched medium was prepared as described in
previous study [17] with modiﬁcation. The HUVECs were placed in
an air-tight, humidiﬁed speciﬁcally modiﬁed container which wass adhesion to HUVECs. Cells were pre-incubated with various concentrations of sevo-
CR (B, C) are shown for ICAM-1 and VCAM-1 expression in HUVECs. (D) HRP-labeled
a spectrophotometer at A450. (E) Cell viability was observed after 30 min incubation
eriments. * indicates a p < 0.01, ** indicates a p < 0.001 compared with untreated cells;
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connected to the sevoﬂurane vaporizer (Blease Medical Equipment
Ltd, Chesham, UK) to make up for the volatilization loss of sevo-
ﬂurane from the anesthetic-enriched medium. The outlet port was
connected to a Datex-Ohmeda 5250 RGM gas analyzer (Drager,
Lubeck, Germany) which measured sevoﬂurane concentration
(1.1%, 3.3%, and 5.5% refer to 0.5 MAC, 1.5 MAC, and 2.5 MAC
respectively). After 10min continuous sevoﬂurane vapor balancing,
air-tight container was sealed to incubate for 0.5 h at 37 C.
2.4. Western blot
Cells were lysed and the protein samples were analyzed by the
BCA method and the equal amounts of protein samples were
resolved on a SDS/PAGE. Gels were transferred on to PVDF and the
membraneswere probedwith antibodies. Membranes were further
incubated with secondary antibodies conjugated to HRP which
were detected by ECL reagent.
2.5. Real-time PCR
Total RNA was isolated using Qiagen RNeasy Mini Kit. qRT-PCR
was performed on complementary DNA generated from 100 ng of
total RNA using the protocol from a qRT-PCR mRNA detection kit
(Roche, Indianapolis, IN, USA). -actin was used as an internal con-
trol. The relative expression level between treatments was thenFig. 2. Sevoﬂurane pretreatment suppresses TNF-a-stimulated NF-kB activation in HUVECs.
and degradation of IkBa (A) and the translocation of NF-kB p65 (B) were measured to exam
Cells were pre-incubated with 1.5 MAC sevoﬂurane for 30 min followed by TNF-a (10 ng
degradation of IkBa in the cytoplasm (C) and cytoplasmic localization of NF-kB p65 (D). Th
indicates a p < 0.01, ** indicates a p < 0.001 compared with untreated cells; D indicates p <calculated using the following equation: relative gene
expression ¼ 2 (DCt sample DCt control). Primer sets for qPCR were as
follows: ICAM-1, 50-CGT GGG GAG AAG GAG CTG AA-30 (forward)
and 50- CAG TGC GGC ACG AGA AAT TG-30 (reverse); and VCAM-1,
50-TGG GCT GTG AAT CCC CAT CT-30 (forward) and 50-GGG TCA
GCG CGT GGA ATT GGT C-30 (reverse); b-actin forward primer 50-
CGC AAA GAC CTG TAC GCC AAC-30 (forward) and 50- CAC GGA GTA
CTT GCG CTC AGG-30 (reverse).
2.6. Evaluation of nitric oxide production
The intracellular NO level was measured using a NO-sensitive
ﬂuorescence probe DAF-FM DA (Calbiochem, San Diego, CA, USA)
by an inverted ﬂorescence microscope (Nikon, Tallahassee, Florida,
USA). Images were processed with image analysis software (NIS-
Elements BR 3.0, Nikon, Tallahassee, Florida, USA). The average
ﬂuorescent density of intracellular areas wasmeasured to index the
NO level. The nitrite concentrations of cell culture medium was
analyzed by using the Nitric Oxide Assay Kit. Absorbance of the
samples was measured at 540 nm using a microplate reader.
2.7. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was carried out by
following the manufacturer's instruction with minor modiﬁcations
(Millipore). Brieﬂy, we added cell with L-NAME or PBS beforeCells were treated with 10 ng/mL TNF-a for different time courses, the phosphorylation
ine the time course of TNF-a-induced NF-kB signaling pathway activation in HUVECs.
/mL) treatment for 4 h. Results of western blot are shown for phosphorylation and
e data were expressed as mean ± SD of the results from three separate experiments. *
0.01 compared with TNF-a-treated cells. (NE: nuclear extracts, CE: cytosolic extracts).
S. Li et al. / Biochemical and Biophysical Research Communications 460 (2015) 879e886882
S. Li et al. / Biochemical and Biophysical Research Communications 460 (2015) 879e886 883incubated with sevoﬂurane for 30 min, then followed by 10 ng/mL
of TNF-a treatment for 4 h. Cells were then incubated with 1%
formaldehyde solution for the crosslinking followed by l0  glycine
to quench unreacted formaldehyde. Cells were collected and only
the nuclear fractions were collected for the sonication. After soni-
cation, samples were incubated with NF-kB antibody and protein A
magnetic beads overnight at 4 C. Input samples without antibody
binding were saved for control. After washing steps, protein and
DNA complexes were eluted and reverse cross-linked. Puriﬁed DNA
samples were subjected to real-time PCR with primers targeting
VCAM-1 promoter region as follow, VCAM-1 forward primer 50-
AAA TCA ATT CAC ATG GCA TA-30, VCAM-1 reverse primer 50-AAG
GGT CTT GTT GCA GAG A-30.2.8. Evaluation of HL-60 cell binding to HUVEC
HL-60 (ATCC, USA) were labeled with HRP and incubated with
TNF-a-stimulated HUVEC at 37 C for 45 min. The culture wells
were washed several times with serum-free media and lysed with
1% Triton solution. 3,30,5,50-Tetramethylbenzidine (TMB, Sigma, St
Louis, MO, USA) substrate was added, and the concentration of HRP
wasmeasured at A450. To quantitate the precise number of adherent
HL-60 cells, a standard curve was constructed by using known
amounts of HRP-labeled HL-60 cells.2.9. Statistical analysis
All data are presented as means ± SD. Student's two-tailed un-
paired t-tests and ANOVAwere used for statistical evaluation of the
data. Sigmastat statistical analysis program was used for data
analysis. P values < 0.05 were considered signiﬁcant.3. Results
3.1. Sevoﬂurane inhibits TNF-a-induced expression of ICAM-1,
VCAM-1 and leukocytes adhesion
As shown in Figure S2, HUVEC were treated with various con-
centrations of TNF-a for different time courses, exposure of HUVEC
to 10 ng/mL TNF-a for 4 h resulted in a signiﬁcant increase of the
protein and mRNA expression of ICAM-1 and VCAM-1. As shown in
Fig. 1, incubation of endothelial cells with sevoﬂurane (0.5 MAC, 1.5
MAC, 2.5 MAC) alone did not signiﬁcantly alter basal adhesion
molecule expression and did not alter leukocytes adhesion in
cultured HUVEC (for data with 1.5 MAC, other values are not
shown). Pretreatment of cells with sevoﬂurane (0.5 MAC, 1.5 MAC,
2.5 MAC) for 30 min reduced TNF-a-induced expression of ICAM-1
and VCAM-1 in a concentration-dependent manner, with the most
signiﬁcant reduction observed at a concentration of 2.5 MAC, the
highest concentration ever tested (Fig. 1AeC). Compared with
control cells, TNF-a increased leukocytes binding by almost 7-fold.
Sevoﬂurane inhibited the adhesion induced by TNF-a indepen-
dently from the concentration used (approximate 4-fold increase
compared with control cells), but its inhibitory effect was barelyFig. 3. Sevoﬂurane induced eNOS phosphorylation and NO production in HUVECs. Cells we
30 min and (B) 1.5 MAC of sevoﬂurane for the indicated times (0, 15, 30, or 60 min), phos
respectively. (C) Representative ﬂuorimetric dye DAF-FM DA-stained cell photomicrographs
DAF-FM DA ﬂuorescence 60 min after incubating with sevoﬂurane (0, 0.5, 1.5 or 2.5 MAC). S
intracellular areas in HUVECs. Each bar represents fold changes in ﬂuorescent density in sevo
in cell culture medium. The data were expressed as mean ± SD of the results from ﬁve separa
cells. D indicates a p < 0.01 compared with 0.5 MAC sevoﬂurane group.stronger with higher concentrations of sevoﬂurane (1.5 MAC and
2.5 MAC) (Fig. 1D).
3.2. Sevoﬂurane suppresses TNF-a-stimulated NF-kB activation in
HUVECs
As shown in Fig. 2, TNF-a rapidly led to phosphorylation of IkBa
and then to degradation of IkBa expression in a time-dependent
manner in the cytoplasm, with a maximal peak at 30 min
(Fig. 2A) and increased NF-kB (p65 sub-unit) nuclear translocation
compared to normal cells with a maximal peak at 60 min (Fig. 2B).
Pretreatment with sevoﬂurane (1.5 MAC) for 30 min reduced the
TNF-a-induced phosphorylation of IkBa and degradation of IkBa
(Fig. 2C). Pretreatment with sevoﬂurane (1.5 MAC) for 30 min
resulted in signiﬁcant cytoplasmic localization of NF-kB p65
(Fig. 2D).
3.3. Sevoﬂurane promotes eNOS phosphorylation and NO
production
As shown in Fig. 3, eNOS phosphorylation was signiﬁcantly
enhanced by sevoﬂurane in a dose dependent manner (Fig. 3A).
When HUVECs were incubated with 1.5 MAC sevoﬂurane for 15, 30
or 60 min eNOS phosphorylation levels peaked after 30 min of
treatment and decreased after 60 min (Fig. 3B). While, the
expression levels of total eNOS and neuronal nitric oxide synthase
(nNOS) remained unchanged. And no inducible nitric oxide syn-
thase (iNOS) was detected (data not shown). Incubation with sev-
oﬂurane (0.5, 1.5 or 2.5 MAC) for 30 min increased intercellular NO
production evidenced as the increases in ﬂuorescence intensity,
which were 170.0 ± 6.1%, 255.9 ± 4.1% and 264.2 ± 5.9% respec-
tively, as compared to the vehicle group (Fig. 3C and D). Accord-
ingly, sevoﬂurane (1.5 or 2.5 MAC) incubation triggered a
comparable increase of NO production in cell culture medium in a
concentration-dependent manner (Fig. 3E).
3.4. Inhibition of eNOS abolishes sevoﬂurane cytoprotection in TNF-
a-stimulated HUVECs
Exposure of endothelial cells to L-NAME (1 mmol/L) for 1 h had
no effect on the expression of CAMs and leukocytes adhesion in
cultured HUVECs (data not shown). Sevoﬂurane-induced eNOS
phosphorylation were abolished by L-NAME without affecting
protein expression of total eNOS (Fig. 4A), sevoﬂurane-induced NO
release was completely inhibited by L-NAME both in intracellular
level and in cell culture medium (Fig. 4BeD). L-NAME almost
completely blocked sevoﬂurane-induced inhibitory effect on the
expression of ICAM-1 and VCAM-1 and the subsequent HL60
binding in TNF-a-treated cells. (Fig. 4EeG). Compared with sevo-
ﬂurane group, L-NAME signiﬁcantly reversed phosphorylation of
IkBa, increased the amount of nuclear NF-kB and decreased the
amount of cytosolic NF-kB in HUVECs (Fig. 4H). With L-NAME
treatment, a higher level of VCAM-1 was detected in the ChIP assay
in TNF-a-treated cells, in shape contrast with sevoﬂurane pre-
treated cells where no VCAM-1 can be detected (Fig. 4I).re incubated with (A) various concentrations of sevoﬂurane (0, 0.5, 1.5, or 2.5 MAC) for
phorylated-eNOS (p-eNOS), total eNOS and nNOS were analyzed by Western blotting
. The content of intracellular NO production was assayed by measuring the intensity of
cale bar represents 100 mm. (D) Quantitative analysis of average ﬂuorescent density of
ﬂurane-treated HUVECs relative to vehicle control. (E) Secreted NO measured by Griess
te experiments. * indicates a p < 0.01, ** indicates a p < 0.001 compared with untreated
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The results of our present studies clearly suggested that eNOS
activation plays a critical role in sevoﬂurane mediated anti-
inﬂammatory response by inhibiting the expression of CAMs.
Speciﬁcally, we found that the down-regulation of adhesion mol-
ecules ICAM-1 and VCAM-1 by sevoﬂurane were abolished by NOS
inhibition and eNOS may directly regulate NF-kB, the upstream
transcription factors of these adhesion molecules. In addition, we
found that sevoﬂurane-induced eNOS activation blocked the
phosphorylation of IkBa, which, in turn, inhibited TNF-a mediated
NF-kB activation. These effects of sevoﬂurane change the expres-
sion proﬁles of ICAM-1 and VCAM-1, molecules affecting leukocyte
adhesion to endothelial cells, a hallmark of inﬂammatory response
in many pathophysiologic status. Our study provide, for the ﬁrst
time, a direct link between eNOS activation and the down-
regulation of CAMs expression in anesthetic sevoﬂurane-induced
anti-inﬂammatory effects.
Vascular endothelial dysfunction plays a pivotal role in the
development and maintenance of inﬂammatory states in various
diseases such as SIRS, ischemia-reperfusion injury and atheroscle-
rosis. The expression of adhesion molecules in endothelial cells is
regulated by activated NF-kB, which can be upregulated in condi-
tions with inﬂammatory mediators induced oxidative stress. NF-kB
also exists in an inactive form when it binds to the inhibitor of
nuclear factor kappa B (IkB) in the cytosol. The proinﬂammatory
cytokine TNF-a causes oxidative stress of vascular endothelial cells
and induces phosphorylation and degradation of IkB, allowing the
activation of NF-kB [18]. In an animal model of acute myocardial
ischemia-reperfusion injury, volatile anesthetic preconditioning
has been shown to attenuate NF-kB activation and subsequent
down-regulation of NF-kB-dependent inﬂammatory cytokines
[19,20]. However, it remains unclear whether sevoﬂurane has the
similar anti-inﬂammatory effects as other volatile anesthetics in
endothelial cells. In our experiments, pretreatment with sevo-
ﬂurane inhibited the subsequent TNF-a-induced phosphorylation
of IkBa and degradation of IkBa, and inhibited NF-kB p65 trans-
location into the nucleus.
Under physiological conditions, NO is an important effective
molecule in the cardiovascular system. Endothelial basal NO for-
mation catalyzed by eNOS plays a critical role in vascular homeo-
stasis affecting vasomotor tone as well as platelet aggregation and
expression of adhesion molecules [11,21]. It has been shown that
eNOS and NO production play critical roles in isoﬂurane pre-
conditioning mediated cardiovascular protection [17]. Until now, it
is not clear whether or not NOS system is directly involved in
sevoﬂurane induced anti-inﬂammatory effects in response to
inﬂammation in endothelial cells. In our study, we found that
sevoﬂurane promoted phosphorylation of eNOS and increased the
production of NO without altering the expression level of total
eNOS and nNOS isoforms. In agreement with our data, Fr€adorf et al.
also conﬁrmed that sevoﬂurane preconditioning induced a pro-
found increase in eNOS phosphorylation in the rat heart in vivo [22].Fig. 4. L-NAME abrogates the anti-inﬂammatory effects of sevoﬂurane in TNF-a-induced en
without 1.5 MAC sevoﬂurane treatment for 30 min, followed by TNF-a treatment for 4 h, a
degree of binding. phosphorylated-eNOS (p-eNOS) and total eNOS (A) were analyzed byWes
by measuring the intensity of DAF-FM DA ﬂuorescence 30 min after incubating with sevoﬂ
measured by Griess in cell culture medium. The data were expressed as mean ± SD of the re
cells, D indicates a p < 0.01 compared with 1.5 MAC sevoﬂurane group. Results of western b
stimulated HUVECs. HRP-labeled leukocytes were added to stimulated HUVEC, and then adh
and degradation of IkBa in the cytoplasm and cytoplasmic localization of NF-kB p65 were ana
samples by NF-kB antibody were subjected to PCR ampliﬁcation by using primers for the
mean ± SD of the results from ﬁve separate experiments. * indicates a p < 0.01, ** indicates a
MAC sevoﬂurane group.Furthermore, in the current study, sevoﬂurane induced increase in
eNOS phosphorylation was blunted by the NOS-inhibitor L-NAME,
which also abolished the effects of sevoﬂurane on the down-
regulation of ICAM-1 and VCAM-1 expression, and on the inhibi-
tion of NF-kB activation, thus abrogated sevoﬂurane mediated
attenuation of leukocytes adhesion. Our results indicate that the
sevoﬂurane induced increased eNOS phosphorylation is function-
ally related to the anti-inﬂammatory effects. Indeed, NO is a potent
inhibitor of leukocyte adhesion, at least in part through decreased
expression of adhesion molecules [23]. We could speculate that the
prevention of organ damage is a consequence of a more controlled
immune reaction that prevents host organs from being attacked by
leukocytes.
There are three NOS isoforms in mammals: neuronal NOS
(nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) [11].
While eNOS plays a protective role and its release is impaired after
ischemia-reperfusion injury [24,25], iNOS derived NO is implicated
in the pathophysiology of the inﬂammatory state inducing vaso-
dilation and increased vascular permeability. As already shown
[12], an increase in NO bioavailability may lead to the down regu-
lation of iNOS expression or even prevent iNOS induction, thereby
limiting or preventing the toxic consequences of the inﬂammatory
response afterward. In the light of this new vision on the key role
played by the cross-talk between n/eNOS and iNOS, it is believed
that, new pharmacological pretreatment, such as sevoﬂurane,
aimed at appropriately generating small amounts of NO before
noxious stimulus can represent a more efﬁcient strategy to reduce
organ functional impairment and tissue damage in the subsequent
inﬂammatory injury, as also indicated by the present study.
In conclusion, this is the ﬁrst report to show that eNOS plays an
important role in sevoﬂurane mediated anti-inﬂammatory
response in endothelial cells. Speciﬁcally, we found that the
down-regulation of adhesion molecules ICAM-1 and VCAM-1 by
sevoﬂurane treatment can be abolished by eNOS phosphorylation
inhibition and eNOS may directly regulate the upstream tran-
scription factors NF-kB. We found that eNOS blocked the phos-
phorylation of IkB, which, in turn, inhibited NF-kB activation incited
by TNF-a in endothelial cells. Therefore, our results suggest that
sevoﬂurane induced eNOS regulates phosphorylation of IkBa and
translocation of NF-kB into nucleus, thereby changing the expres-
sion of ICAM-1 and VCAM-1, and affecting leukocytes adhesion to
endothelial cells.
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